Latest news with #NovoNordisk
Mint
2 hours ago
- Business
- Mint
How Ozempic's maker lost its grip on the obesity market it created
In 2023, Novo Nordisk was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground. Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year. If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network. 'Everyone wants to be the first footprints on the empty beach," said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes." Lars Fruergaard Jørgensen, who was pushed out as CEO of Novo Nordisk earlier this Nordisk lost market share after miscalculating demand in the launch of weight-loss drug Wegovy. A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity. Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly. 'Novo is always a step behind," said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares. One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs. Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity. It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing." The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses. The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk. Eli Lilly activated a manufacturing plant in Concord, N.C., to keep up with a surge in demand for Mounjaro and Zepbound. The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight. Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap. Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion. The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections. Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug. Novo Nordisk's Wegovy has been surpassed in weekly U.S. prescriptions by Lilly's Zepbound. Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly. 'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets," said BMO Capital Markets analyst Evan David Seigerman. The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals. Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said. More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans. Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO. Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors. 'Now they need somebody more business-driven," Sindbæk said. Write to Peter Loftus at and Noemie Bisserbe at
Wall Street Journal
3 hours ago
- Business
- Wall Street Journal
How Ozempic's Maker Lost Its Grip on the Obesity Market It Created
In 2023, Novo Nordisk NVO -2.61%decrease; red down pointing triangle was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly LLY -0.80%decrease; red down pointing triangle—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground. Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year. If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network. 'Everyone wants to be the first footprints on the empty beach,' said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes.' A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity. Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly. 'Novo is always a step behind,' said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares. One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs. Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity. It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing.' The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses. The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk. The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight. Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap. Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion. The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections. Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug. Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly. 'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets,' said BMO Capital Markets analyst Evan David Seigerman. The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals. Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said. More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans. Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO. Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors. 'Now they need somebody more business-driven,' Sindbæk said. Write to Peter Loftus at and Noemie Bisserbe at
Yahoo
5 hours ago
- Business
- Yahoo
3 Surprising Stocks That Have More Than Doubled in 2025
Hims & Hers Health, FuboTV, and Groupon have all more than doubled in 2025. These companies took very different paths to their stellar year-to-date results. Hims & Hers Health has had to make some major changes to its business in recent months, but it's still positioned for healthy growth. 10 stocks we like better than Hims & Hers Health › This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 -- and some of the names will surprise you. Hims & Hers Health (NYSE: HIMS), FuboTV (NYSE: FUBO), and Groupon (NASDAQ: GRPN) -- yes, that Groupon -- are among those 14 stocks that have more than doubled their shareholder money this year. All three have taken entirely different routes to thumping the market this year. After it posted a whopping 183% gain last year, it wouldn't have been shocking to see Hims & Hers Health stock take a breather in 2025. The online healthcare platform that got its start by making it easier for people to secure prescriptions for erectile dysfunction drugs and hair growth treatments blew up last year due to the popularity of its compounded GLP-1 injectables for weight loss. Because Novo Nordisk (NYSE: NVO) was unable to produce Wegovy fast enough to meet surging demand, the Food and Drug Administration put the drug on its official shortage list. That opened up a legal loophole for businesses that operate as compounding pharmacies to produce and sell their own versions of the patented treatment. Hims & Hers cashed in with its own GLP-1 drug, featuring the same active ingredient found in Wegovy and Ozempic -- semaglutide. More importantly, it offered that treatment at more aggressive discounts than Novo Nordisk was putting on the name-brand versions. Hims & Hers Health was doing fine even before it hopped on the GLP-1 bandwagon in spring 2024. Its revenue has risen by at least 65% in each of the last six years. However, the popular new product helped it accelerate its top-line growth in 2024, and it continued to speed up in the first quarter of this year, when revenue more than doubled. This year began with early gains. Late in 2025, incoming President Donald Trump said he would tap Martin Makary to head the FDA. Makary served on the board of a company that also was into GLP-1 compounding, so the market took the view that Hims & Hers' upticks would continue even after Novo Nordisk finished ramping up Wegovy production to a level that could meet patient demand. Matters didn't exactly play out that way. Hims & Hers stock scored an all-time high on Feb. 19, but within weeks, the share price was cut by more than half. Novo Nordisk's production of semaglutide reached the volume necessary to close the FDA loophole, and it seemed as if the semaglutide compounding ride was ending for Hims & Hers and its peers. Then, two things happened that brought investors back. Novo Nordisk cut deals with a small number of telehealth companies, including Hims & Hers, giving them the right to sell discounted monthly subscriptions of Wegovy. Hims & Hers also reported a blowout first quarter earlier this month, and management forecast that the balance of its business outside of compounding would still grow at a healthy 30% clip this year. One of the first stocks to double in 2025 was FuboTV. The company behind the namesake sports-centric live TV streaming service more than tripled in the first week of trading after it struck a transformative deal with Disney (NYSE: DIS). Fubo had just 1.7 million paid subscribers heading into this year, less than 10% of the roughly 20 million households paying for live TV streaming services that digitally recreate versions of the familiar cable or satellite TV bundle. The stock entered this year trading 98% below the peak it touched in late 2020, when management had dreams of turning the company into a streaming platform with an online sportsbook component. Fubo had to fold that hand, but it still had an ace up its sleeve. Disney and two other media giants had been hoping to launch Venu Sports, a monthly subscription service that would bundle content from all of their sports properties -- anchored by Disney's majority-owned ESPN -- into a digital subscription costing $43 a month. But Fubo sued, and last summer, it won an injunction blocking Venu's launch. In a move to clear that obstacle, Disney offered to acquire a 70% stake in FuboTV. The House of Mouse will contribute its larger Hulu + Live TV service -- with 4.6 million subscribers -- to Fubo. Fubo will also receive $220 million from the Venu partners in exchange for dropping its lawsuit. The deal with Disney isn't expected to close until the the first half of next year, but if it falls apart, Fubo would collect another $130 million. It also has access to a $145 million term loan from Disney. Then something amusing happened. Within days of the deal that would give Disney a majority stake in Fubo but keep the smaller company's management in control, the three Venu partners decided not to go through with their digital bundle. Fubo has had its share of growing pains, but it's in an interesting win-win situation here. However, the shares have been meandering along at levels well below those they reached during that initial spike in January. Finally, we have a more conventional doubling chart. Groupon's rise this year can be traced to two specific events: the fourth-quarter earnings report it delivered in early March, and the first-quarter report it released earlier this month. After eight consecutive years of declining revenues, the online discounter of local experiences is starting to turn the corner. Revenue did decline 5% in Q4 2024, but gross billings for its flagship North American business climbed 8%. Its latest report showed even more improvement. Groupon posted a strong and unexpected profit. Analysts now predict it will make a return to revenue growth this year, and that its improvements will accelerate in 2026. Its business model could also prove to be attractive to lead-seeking businesses if the U.S. economy loses steam -- so don't discount this discounter. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Rick Munarriz has positions in Walt Disney. The Motley Fool has positions in and recommends Walt Disney and fuboTV. The Motley Fool has a disclosure policy. 3 Surprising Stocks That Have More Than Doubled in 2025 was originally published by The Motley Fool
Yahoo
11 hours ago
- Business
- Yahoo
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Veru's muscle-preserving obesity drug enobosarm, when combined with Novo Nordisk's Wegovy, may have less gastrointestinal side effects at the dose planned for pivotal testing than Wegovy alone, according to safety results from a Phase 2 clinical trial the company released Wednesday. Fewer people receiving either of two doses of enobosarm and Wegovy experienced nausea or heartburn than those taking just Wegovy, and, at the enobosarm dose planned for Phase 3 testing, fewer had diarrhea or vomiting, Veru said. However, the company reported more volunteers given enobosarm had elevated liver enzymes, although levels subsequently dropped during the trial. Veru shares rose significantly in morning trading Wednesday, although at around 60 cents a share they remain well below the $1.28 hit before release of topline weight-loss data in January. That data suggested enobosarm helps with body composition, but doesn't increase weight loss when used with Wegovy. The safety data from the trial had remained 'blinded' to the company and researchers until participants could complete an extension to the main 16-week stage of the trial. The 168-person trial sought to show that adding enobosarm to Wegovy could result in less loss of lean muscle mass than Wegovy. Body composition is an emerging issue in obesity treatment as Wegovy and Eli Lilly's Zepbound also cut lean muscle mass alongside fat, which in older patients could raise the risk of premature frailty. Veru's trial focused specifically on people with obesity at least 60 years old. While adding enobosarm to Wegovy didn't increase weight loss versus Wegovy and a placebo, it kept lean body mass loss to 1.2%, significantly less than the 4.1% lean body mass loss seen with the Wegovy plus placebo arm. Fewer people who took enobosarm and a placebo also saw substantial losses in their stair-climb power, a measure of physical function. Veru tested two doses of enobosarm, 3 and 6 milligrams daily, alongside weekly shots of Wegovy. Based on the data seen so far, Veru will take the 3 milligram dose into a Phase 3 trial because the 6 milligram dose 'did not provide any additional benefit.' At that 3 milligram level, only one trial participant experienced elevated liver enzymes — a mild case in which the individual's levels returned to baseline while they were still taking the drug. Meanwhile, the company also said it is preparing a 'novel, patentable, modified release oral formulation' for Phase 3 testing and potential commercialization that will undergo Phase 1 trials in coming weeks. The company said it believes the formulation patent from the new version will extend its market exclusivity to 2045. Enobosarm has been tested in the past as a drug to prevent muscle wasting in people with lung cancer and other disease settings.
Globe and Mail
13 hours ago
- Business
- Globe and Mail
Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes
DelveInsight's 'Noonan Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Noonan Syndrome, historical and forecasted epidemiology as well as the Noonan Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Noonan Syndrome, offering comprehensive insights into the Noonan Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Noonan Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Noonan Syndrome therapies. Additionally, we cover the landscape of Noonan Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Noonan Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Noonan Syndrome space. Some of the key facts of the Noonan Syndrome Market Report: The Noonan Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In May 2025, Novo Nordisk's once-weekly Sogroya (somapacitan) demonstrated non-inferiority compared to the once-daily growth hormone Norditropin (somatropin) in a Phase III trial focused on pediatric growth disorders. The Danish company reported that Sogroya enhanced the annual growth rate in pre-pubertal children born small for gestational age (SGA), those with Noonan syndrome (NS), or those with idiopathic short stature (ISS), as shown in the Phase III REAL8 basket study (NCT05330325). Key Noonan Syndrome Companies: Sanofi, Novo Nordisk A/S, BioMarin Pharmaceutical, and others Key Noonan Syndrome Therapies: MAXOMAT ®, somatropin, Vosoritide Injection, and others The Noonan Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Noonan Syndrome pipeline products will significantly revolutionize the Noonan Syndrome market dynamics. The prevalence of Noonan Syndrome Occurs in approximately 1 in 1,000 to 2,500 live births worldwide Noonan Syndrome is One of the more common genetic syndromes affecting multiple systems Noonan Syndrome Affects males and females equally, with no significant gender bias Caused by mutations in genes involved in the RAS/MAPK pathway, including PTPN11, SOS1, RAF1, and others About 50% of cases are due to mutations in the PTPN11 gene Noonan Syndrome Overview Noonan Syndrome is a genetic disorder that affects multiple parts of the body. It is characterized by distinctive facial features, short stature, heart defects (such as pulmonary valve stenosis), developmental delays, and other health issues. The condition is caused by mutations in genes involved in the RAS/MAPK signaling pathway, which plays a key role in cell growth and development. Noonan Syndrome occurs in both males and females and varies widely in severity. Early diagnosis and management can help address the associated complications and improve quality of life. Get a Free sample for the Noonan Syndrome Market Forecast, Size & Share Analysis Report: Noonan Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Noonan Syndrome Epidemiology Segmentation: The Noonan Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Noonan Syndrome Prevalent Cases of Noonan Syndrome by severity Gender-specific Prevalence of Noonan Syndrome Diagnosed Cases of Episodic and Chronic Noonan Syndrome Download the report to understand which factors are driving Noonan Syndrome epidemiology trends @ Noonan Syndrome Epidemiology Forecast Noonan Syndrome Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Noonan Syndrome market or expected to get launched during the study period. The analysis covers Noonan Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Noonan Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Noonan Syndrome Therapies and Key Companies Discover more about therapies set to grab major Noonan Syndrome market share @ Noonan Syndrome Treatment Landscape Noonan Syndrome Market Drivers Rising Diagnosis Rates Advancements in Genetic Research Pharmaceutical Collaborations Government Initiatives Noonan Syndrome Market Barriers Lack of Approved Therapies High Treatment Costs Limited Awareness Genetic Heterogeneity Scope of the Noonan Syndrome Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Noonan Syndrome Companies: Sanofi, Novo Nordisk A/S, BioMarin Pharmaceutical, and others Key Noonan Syndrome Therapies: MAXOMAT ®, somatropin, Vosoritide Injection, and others Noonan Syndrome Therapeutic Assessment: Noonan Syndrome current marketed and Noonan Syndrome emerging therapies Noonan Syndrome Market Dynamics: Noonan Syndrome market drivers and Noonan Syndrome market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Noonan Syndrome Unmet Needs, KOL's views, Analyst's views, Noonan Syndrome Market Access and Reimbursement Table of Contents 1. Noonan Syndrome Market Report Introduction 2. Executive Summary for Noonan Syndrome 3. SWOT analysis of Noonan Syndrome 4. Noonan Syndrome Patient Share (%) Overview at a Glance 5. Noonan Syndrome Market Overview at a Glance 6. Noonan Syndrome Disease Background and Overview 7. Noonan Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Noonan Syndrome 9. Noonan Syndrome Current Treatment and Medical Practices 10. Noonan Syndrome Unmet Needs 11. Noonan Syndrome Emerging Therapies 12. Noonan Syndrome Market Outlook 13. Country-Wise Noonan Syndrome Market Analysis (2019–2032) 14. Noonan Syndrome Market Access and Reimbursement of Therapies 15. Noonan Syndrome Market Drivers 16. Noonan Syndrome Market Barriers 17. Noonan Syndrome Appendix 18. Noonan Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
